GlassScriptPhysician profile
Brandi Ratliff
NPI 1902480643
$3,432.97
in general payments reported to CMS, 2019-2025
22 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.94 · 2023: $1,372 · 2024: $864 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,366 · Education: $15.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,365.56 |
| Education | $15.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $564.62 | 2022-2025 | |
| Janssen Biotech, INC. | $292.16 | 2022-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $286.58 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $250.00 | 2023-2024 | Dupixent |
| Glaxosmithkline, LLC. | $238.19 | 2023 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $237.30 | 2023-2025 | Epclusa |
| Inspire Medical Systems, INC. | $226.09 | 2023-2024 | Inspire |
| Evoke Pharma, INC. | $215.96 | 2022-2025 | Gimoti |
| Vanda Pharmaceuticals INC. | $215.66 | 2025 | Fanapt |
| Abbott Laboratories | $137.50 | 2023 | Freestyle Libre 3 |
| Dexcom, INC. | $129.73 | 2024 | Dexcom G7 Gss (161) |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | |
| Kyowa Kirin, INC. | $125.00 | 2025 | |
| Axsome Therapeutics, INC. | $81.47 | 2023-2025 | Auvelity |
| Genzyme Corporation | $60.18 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $57.46 | 2024 | Linq II |
| Phathom Pharmaceuticals, INC. | $52.54 | 2024-2025 | Voquezna |
| Pfizer INC. | $47.38 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.15 | 2024 | Xifaxan, Relistor |
| Organon LLC | $19.85 | 2023 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $18.21 | 2024 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $15.94 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Ratliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.